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Abstract: Glycosylation is a ubiquitous post-translational
modification, present in over 50% of the proteins in the
human genome,[1] with important roles in cell–cell communi-
cation and migration. Interest in glycome profiling has
increased with the realization that glycans can be used as
biomarkers of many diseases,[2] including cancer.[3] We report
here the first tomographic imaging of glycosylated tissues in
live mice by using metabolic labeling and a gadolinium-based
bioorthogonal MRI probe. Significant N-azidoacetylgalactos-
amine dependent T1 contrast was observed in vivo two hours
after probe administration. Tumor, kidney, and liver showed
significant contrast, and several other tissues, including the
pancreas, spleen, heart, and intestines, showed a very high
contrast (> 10-fold). This approach has the potential to enable
the rapid and non-invasive magnetic resonance imaging of
glycosylated tissues in vivo in preclinical models of disease.
Various probes have been reported for imaging glycosylation
in vivo, including antibodies,[4] peptides,[5] boronic acid deriv-
atives,[6] and lectins.[7] Most approaches give a static view of
cell-surface glycosylation. We, and others, have used meta-
bolic glycan labeling[8] in combination with bioorthogonal
reactions[9] to image the dynamics of glycan biosynthesis
in vivo. We demonstrated non-invasive imaging of tumor
glycosylation in live mice[10] by metabolic labeling of tumor
glycans with azido sugars followed by Staudinger ligation with
a biotinylated phosphine and subsequent imaging using
fluorescent or radionuclide-labeled avidins. More recently,
we described “double-click” reagents,[11] where azido-modi-
fied cell-surface glycoproteins were detected using a bivalent
double-click bioorthogonal probe. The latter consisted of
a strained tetramethoxydibenzocyclooctyne (TMDIBO),[12]
which reacted specifically with azido sugar labeled glycans,[9]
and a trans-cyclooctene (TCO), which reacted very rapidly
with a fluorescently labeled tetrazine for fluorescence imag-
ing (FLI). FLI gives high sensitivity and throughput;[13]
however, a limitation is light absorption and scattering,
which prevents deep imaging in opaque organisms such as
mice.
Recently, cells metabolically labeled with N-azidoacetyl-
mannosamine were imaged by magnetic resonance imaging
(MRI) and a xenon (129Xe) biosensor. The azido group in cell-
surface sialic acid residues was detected using a bifunctional
reagent incorporating bicyclo[6.1.0]nonyne, which reacted
with the azido group, and a cryptophane, which bound
hyperpolarized 129Xe. Bound xenon was detected by magnet-
ization transfer measurements between free and bound xenon
(hyper-CEST).[14] Although hyperpolarized 129Xe is very
sensitive to MR detection, the change in signal intensity was
relatively small (ca. 30–50%), and only demonstrated for
encapsulated cells in a bioreactor. A CEST-based label-free
method for imaging underglycosylated mucin-1 expression
in vivo has also been described recently.[15]
Our aim was to develop a probe for the tomographic, non-
invasiveMR imaging of metabolically labeled glycans in mice.
A previously reported MRI probe, consisting of a phosphine
conjugated to a gadolinium chelate,[11] gave no detectable
azido sugar dependent contrast in vivo owing to high levels of
non-specific binding, which we attributed to its hydrophobic-
ity. We describe here TMDIBO–Lys–Gd (2 ; Figure 1), a novel
water-soluble probe that combines a strained cyclooctyne
TMDIBO linked, via a hydrophilic lysine linker, to a gadoli-
nium DOTA chelate, a clinically approved MRI contrast
agent.[16] This probe was used to image metabolically labeled
cell-surface glycans on tumor cells in vitro and in vivo. The
probe also showed significant labeling of other mouse tissues,
including the pancreas, spleen, kidney, liver, and gut.
The T1 relaxivity of 2 (Figure 1) in buffer at 7 Twas 6.3
0.1 mm¢1s¢1, similar to published values for Gd DOTA
complexes.[16] The reactivity of 2 with cell-surface azido
sugar labeled glycans was determined by culturing Lewis lung
(LL2) adenocarcinoma cells with N-azidoacetylgalactos-
amine (Ac4GalNAz, 1; Figure 1) for 24 h, and then incubating
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themwith 2 for 45 min, after which the cells were washed. The
R1 (1/T1) relaxation rates were measured in pelleted cells that
had been incubated with (+ /+ /¢) or without (+ /¢/¢) 1 and/
or 2 (+ /+ /+ , + /¢/+ ; Figure 2). There was a significant
increase (P< 0.005) in R1 in azido sugar (1) treated LL2 cells
that had been incubated with 2 (+ /+ /+ , 1.38 0.10 s¢1),
when compared with cells not cultured with the azido sugar
(+ /¢/+ , 0.79 0.02 s¢1) or with cells not incubated with
either 1 or 2 (+ /¢/¢, 0.64 0.03 s¢1, P< 0.001). The small
increase in R1 (by a factor of 1.23 0.01) between cells that
had not been treated with either 1 or 2 (+ /¢/¢) and cells
incubated with 2 alone (+ /¢/+) showed that there were only
low levels of non-specific binding of 2. This was considerably
less than observed previously with a fluorescently labeled
version of TMDIBO, where this ratio was 3.3 0.1.[11]
Mice with flank tumors, obtained by subcutaneous
injection of LL2 cells, were injected daily, for three days,
with Ac4GalNAz (1; 300 mgkg
¢1, i.p.) or with solvent vehicle,
and then injected with 2 (0.25 mmolkg¢1, i.v.; gadolinium-
based contrast media are used clinically at 0.1–0.3 mmolkg¢1)
on day 4.[17] The metabolic labeling of glycans with 1 and
subsequent bioorthogonal detection with 2 was confirmed by
ICP-MS measurements of the gadolinium content in excised
tissues (Figure 3) obtained after the imaging experiments
(Figures 4 and 5), and 24 h after the injection of 2. Most
tissues showed N-Ac4GalNAz dependent labeling. The gado-
linium content was highest in the kidney (29.9 5.8 nmol Gd
per gram of tissue). However, about one third of this was due
to the non-specific retention of 2 and thus not N-Ac4GalNAz
dependent (10.9 2.2 nmol Gd per gram of tissue), and
metabolic labeling was relatively modest (2.7 0.5-fold
increase in gadolinium content in animals injected with
1 and 2 (+ /+) compared with those injected with 2 alone
(¢/+)). The high background signal in the kidney is likely due
to this organ being the preferred clearance route for
molecules < 1 kDa. The liver also showed relatively high
levels of non-specific retention of 2 (4.5 0.8 nmol Gd per
gram of tissue) and similar levels ofN-Ac4GalNAz dependent
labeling as the kidney (2.3 0.3-fold). The levels of kidney
and liver labeling are in agreement with our previous work on
FLI.[11] Other tissues showed very low levels of non-specific
Figure 2. MR imaging of cell-surface glycosylation in vitro. a) T2-
weighted images and b) corresponding maps of the R1 relaxation rates
(1/T1). The images were obtained from cell pellets of untreated cells
(+ /¢/¢), cells treated with solvent vehicle and 2 (1.0 mm, for 45 min
at 37 8C; + /¢/+), or cells incubated with 1 (50 mm, for 24 h at 37 8C)
and 2 (1.0 mm, for 45 min at 37 8C; + /+ /+). The R1 rates were also
measured in the buffer in which the cells had been suspended (¢/¢/
¢) and in a buffer to which 2 had been added (1.0 mm ; ¢/¢/+).
Data represent the mean standard error of the mean (SEM) (n=3).
**P<0.01, ***P<0.005, ****P<0.001. Two-tailed unpaired T-test
with Mann–Whitney correction.
Figure 3. Gadolinium concentrations in metabolically labeled mouse
tissues. The Gd content of excised tissues was determined by
inductively coupled plasma mass spectrometry (ICP-MS). Tissues
were obtained from control mice (¢/+) and Ac4GalNAz treated mice
(+ /+) after the imaging experiments and 24 h after injection of 2
(Figure 1). The Gd content was normalized to the wet tissue weight.
Data represent the meanSEM (n=5). *P<0.05, **P<0.01,
***P<0.005. Two-tailed unpaired T-test with Mann–Whitney correc-
tion.
Figure 1. Labeling of cell-surface glycans with an MRI-detectable
probe. Mice were injected daily with peracetylated N-azidoacetylgalac-
tosamine (Ac4GalNAz, 1). Azido-labeled cell-surface glycoproteins were
then detected in vivo by subsequent reaction with a bioorthogonal MRI
contrast agent, TMDIBO–Lys–Gd (2).
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background retention of 2 and consequently high levels of N-
Ac4GalNAz dependent labeling. The gadolinium concentra-
tion ratios for tissues from animals injected with N-
Ac4GalNAz (+ /+) relative to those injected with the solvent
vehicle (¢/+) were 57 8 for the heart, 39 4 for spleen,
14 2 for the pancreas and the small and large intestine, and
5 1 for the lungs. Tumors showed much higher levels of non-
specific retention of 2, and therefore, the gadolinium concen-
tration ratio was much lower (3.3 1.1). Glycan-labeling
methods based on the delivery of labeled sugars using
targeted liposomes[18] could be used to improve tumor
selectivity.
Serum showed significant metabolic labeling (the serum
gadolinium concentration ratio for animals injected with N-
Ac4GalNAz and those injected with the solvent vehicle was
12 1, P< 0.005; Figure 3). Metabolic labeling of mouse
serum[19] is thought to result from the incorporation of azido
sugars into the major glycosylated proteins present.[20] We
estimated the contribution of labeled serum glycoproteins to
labeling of the small intestine, spleen, kidney, and liver from
the serum contents of these tissues, which have been
estimated to be 5.0, 9.2, 19.1, and 20.2% of the tissue
volume, respectively.[21] The contribution of labeled serum
proteins was estimated to be only 1.0, 2.4, 1.0, and 3.4% of the
total tissue glycan labeling, respectively. Tumors have a much
larger interstitial volume fraction (20–40%),[22] and their
leaky neovasculature results in the retention of macromole-
cules.[23] However, the contribution to tumor labeling, due to
retention of labeled serum proteins, was estimated to be only
15–30% of the total.
T2-weighted images and T1 relaxation rate (R1) maps
(Figure 4) were acquired in vivo before and at 2 and 24 h post
injection of 2. The relaxation rates (R1) for water protons in
the tumor, kidney, and liver (Figure 4) were significantly
higher in animals injected with 1 and 2 (+ /+) than for the
controls injected with the vehicle and 2 (¢/+), demonstrating
Figure 4. Imaging tissue glycosylation in vivo using MRI T1 maps. T2-weighted (gray scale) images (a, e) and T1 maps (pseudo-colored; a, e) of
representative mice injected with the vehicle and 2 (¢/+) or 1 and 2 (+ /+), showing metabolic labeling of tumor (triangles), kidney (arrows),
and liver (chevrons), 2 and 24 h after injection of 2. a) Axial and e) coronal images are shown. The kinetics of N-Ac4GalNAz dependent contrast
formation were analyzed for regions of interest defined on the T2-weighted images for the tumor (b), muscle (c), kidney cortex (f), medulla (h),
and liver (j), and the corresponding data were normalized to the muscle data (d, g, i, k). Data in (b)–(d) and (f)–(k) represent meanSEM
(n=5). The relaxation rate R1 (1/T1) is expressed in s
¢1. *P<0.05, **P<0.01. Two-tailed unpaired T-test with Mann–Whitney correction.
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non-invasive MRI detection of N-Ac4GalNAz dependent
tissue labeling in vivo (Figure 4b–k).
The tumor contrast observed 2 h after probe injection was
similar to that reported recently at 24 h after administration
of a boronic acid basedMRI contrast agent for detecting sialic
acid in a murine model of melanoma.[6] Other organs also
showed appreciable labeling (Figure 4e, + /+); however,
analysis of the T1maps was difficult owing to organ motion. A
semi-quantitative estimate of labeling based on coronal T1-
weighted images acquired in vivo (Figure 5 and Movie S1) 2 h
post administration of 2 indicated significant azido sugar
dependent labeling of tumor (P< 0.05), kidney (P< 0.05), gut
(P< 0.005), liver (P< 0.05), and spleen (P< 0.005).
The gadolinium concentrations in tumor, kidney, and liver
were estimated using the T1 relaxivity of 2, and the relaxation
rates of these tissues measured in vivo (Figure 4). This gave
gadolinium concentrations of 42 3, 80 6 and 93 12 mm,
respectively, at 2 h post administration of 2 and 15 1, 38 3,
and 17 1 mm at 24 h. The gadolinium concentration in the
kidney measured ex vivo after 24 h was 30 6 mm (Figure 3),
which is comparable with that estimated by the in vivo
experiment. There was poorer agreement between the
estimated in vivo concentrations in the tumor and liver at
24 h and those measured ex vivo, which were 1.8 0.4 and
11 1 mm, respectively (Figure 3). However, this can be
explained by the fact that the estimated minimum MRI-
detectable tissue concentration of gadolinium is approxi-
mately 10 mm.[24]
In summary, the gadolinium-labeled bioorthogonal probe
described here can be used for the non-invasive in vivo
imaging of tissue glycosylation by magnetic resonance imag-
ing. Most tissues showed only low levels of non-specific
retention of TMDIBO–Lys–Gd (2), and a significant N-
azidoacetylgalactosamine dependent contrast was observed
within two hours of probe administration. As altered cell-
surface glycosylation is a hallmark of disease, particularly
cancer, and MRI is a widely used imaging technique, this
novel method may enable the rapid assessment of disease-
related changes in glycosylation in vivo.
Figure 5. Imaging tissue glycosylation in vivo using T1-weighted MRI. Coronal T1-weighted images, before (a) and 2 h after (b) the injection of 2.
Maximum intensity projection of T1-weighted signals (c) from representative mice injected with solvent vehicle and 2 (¢/+) or 1 and 2 (+ /+).
Coronal T1-weighted images (b, left to right) are displayed from the ventral towards the dorsal side. Maximum intensity projections (c) onto the
sagittal (left) and coronal (right) planes. b) Metabolic labeling was observed in the tumor (white arrows), kidney (cyan), liver (orange), gut
(purple), and spleen (green) 2 h after the injection of 2. Bladder and gallbladder are indicated by red and yellow arrows, respectively. d) The N-
Ac4GalNAz dependent contrast was analyzed semi-quantitatively, using regions of interest defined in the T1-weighted images for the tumor,
kidney, gut, liver, and spleen; the mean signal intensity (MSI) for these tissues was divided by the MSI of muscle. Data represent meanSEM
(n=4). *P<0.05, **P<0.005. Two-tailed unpaired T-test with Mann–Whitney correction.
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